Open AccessLong‐term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia
Author(s) -
Ono Takaaki,
Takeshita Akihiro,
Kishimoto Yuji,
Kiyoi Hitoshi,
Okada Masaya,
Yamauchi Takahiro,
Tsuzuki Motohiro,
Horikawa Kentaro,
Matsuda Mitsuhiro,
Shinagawa Katsuji,
Monma Fumihiko,
Ohtake Shigeki,
Nakaseko Chiaki,
Takahashi Masatomo,
Kimura Yukihiko,
Iwanaga Masako,
Asou Norio,
Naoe Tomoki
Publication year - 2012
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2012.02390.x
Subject(s) - acute promyelocytic leukemia , medicine , cytarabine , anthracycline , leukemia , cumulative incidence , incidence (geometry) , gastroenterology , oncology , retinoic acid , cancer , transplantation , biochemistry , chemistry , physics , breast cancer , optics , gene
Studies focused on elderly acute promyelocytic leukemia (APL) are relatively limited. To evaluate prognostic impact in elderly APL, we compared the long-term outcome of elderly APL patients (60-70 years) with younger patients (15-59 years) treated with all-trans retinoic acid combined with anthracycline and cytarabine in the Japan Adult Leukemia Study Group (JALSG) APL97 study. Of 283 evaluable patients, 46 (16.3%) were elderly who had more frequent lower platelet (P = 0.04), lower albumin (P = 0.006) and performance status 3 (P = 0.02), higher induction death rate due to differentiation syndrome (P = 0.03), and non-relapse mortality (NRM) during consolidation therapy (P = 0.001). Overall survival was significantly inferior in elderly patients (P = 0.005), but disease-free survival and cumulative incidence of relapse were not. Better therapeutic approaches should be considered to reduce NRM during induction and consolidation therapy in elderly APL. This study was registered at http://www.umin.ac.jp/ctrj/ under C206.